Who
Daniella Beckman
Director
Company insider
Files Form 4 as: Director, Vor Biopharma; Director, Upstream Bio; Chief Financial Officer, Tango Therapeutics; Director, Blueprint Medicines; Director, Translate Bio; Director, 5:01 Acquisition; SVP, CFO and Treasurer, Idenix Pharmaceuticals.
In numbers
- Trades disclosed
- 66
- Buys
- 0
- Sells
- 5
- Bought
- $0
- Sold
- $325K
- Companies
- 7
- Companies where not an officer
- 5
- First trade
- 2 Jun 2011
- Last trade
- 11 Jun 2026
- Last filed
- 12 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 11 Jun 2026filed 12 Jun 2026 | VOR Vor Biopharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —53,283 at $0.00 | filing |
| 11 Jun 2026filed 12 Jun 2026 | VOR Vor Biopharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —53,283 at $0.00 | filing |
| 9 Jun 2026filed 11 Jun 2026 | UPB Upstream Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —17,096 at $0.00 | filing |
| 9 Jun 2026filed 11 Jun 2026 | UPB Upstream Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —17,096 at $0.00 | filing |
| 3 Feb 2026filed 4 Feb 2026 | TNGX Tango TherapeuticsBiotechnology | SEC FORM 4 Sold | $125K10,204 at $12.26 | filing |
| 3 Feb 2026filed 4 Feb 2026 | TNGX Tango TherapeuticsBiotechnology | SEC FORM 4 Sold | $1,457113 at $12.90 | filing |
| 3 Feb 2026filed 4 Feb 2026 | TNGX Tango TherapeuticsBiotechnology | SEC FORM 4 Sold | $125K10,204 at $12.26 | filing |
| 3 Feb 2026filed 4 Feb 2026 | TNGX Tango TherapeuticsBiotechnology | SEC FORM 4 Sold | $1,458113 at $12.90 | filing |
| 2 Feb 2026filed 4 Feb 2026 | TNGX Tango TherapeuticsBiotechnology | SEC FORM 4 Code A | —44,330 at $0.00 | filing |
| 2 Feb 2026filed 4 Feb 2026 | TNGX Tango Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —265,980 at $0.00 | filing |
| 2 Feb 2026filed 4 Feb 2026 | TNGX Tango Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —265,980 at $0.00 | filing |
| 2 Feb 2026filed 4 Feb 2026 | TNGX Tango TherapeuticsBiotechnology | SEC FORM 4 Code A | —44,330 at $0.00 | filing |
| 17 Jul 2025filed 21 Jul 2025 | Blueprint Medicinesoption or derivative | SEC FORM 4 Code D | —7,000 | filing |
| 17 Jul 2025filed 21 Jul 2025 | Blueprint Medicinesoption or derivative | SEC FORM 4 Code D | —5,300 | filing |
| 17 Jul 2025filed 21 Jul 2025 | Blueprint Medicinesoption or derivative | SEC FORM 4 Code D | —5,300 | filing |
| 17 Jul 2025filed 21 Jul 2025 | Blueprint Medicinesoption or derivative | SEC FORM 4 Code D | —4,570 | filing |
| 17 Jul 2025filed 21 Jul 2025 | Blueprint Medicines | SEC FORM 4 Code D | —3,902 | filing |
| 17 Jul 2025filed 21 Jul 2025 | Blueprint Medicines | SEC FORM 4 Code U | —10,842 | filing |
| 18 Jun 2025filed 24 Jun 2025 | Blueprint Medicines | SEC FORM 4 Code A | $500K3,902 at $128.12 | filing |
| 10 Jun 2025filed 12 Jun 2025 | UPB Upstream Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —17,096 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.